Pharmaceutical

AbbVie’s migraine medication Qulipta gets positive CHMP opinion

The medication could be a strong contender in the EU migraine market as a daily CGRP antagonist for migraines.

Jun 23, 2023 - 20:00
AbbVie’s migraine medication Qulipta gets positive CHMP opinion
The medication could be a strong contender in the EU migraine market as a daily CGRP antagonist for migraines.
Read the original article

Tags:

Previous Article

STAT+: European companies outline opposition to proposed overhaul of pharma policy

Next Article

Intercept winds down NASH programme after FDA pulls plug on Ocaliva

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: Novartis R&D hub’s name change reflects strategy shift; Lilly’s Mounjaro backed by U.K. watchdog

STAT+: Pharmalittle: Novartis R&D hub’s name change ref...

Sep 8, 2023

FDA fast tracks MimiVax’s glioblastoma vaccine SurVaxM

FDA fast tracks MimiVax’s glioblastoma vaccine SurVaxM

Oct 13, 2023

STAT+: Devoted Health’s losses in Medicare Advantage persist

STAT+: Devoted Health’s losses in Medicare Advantage pe...

Feb 5, 2024